{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T16:13:04Z","timestamp":1793463184474,"version":"4.5.0"},"reference-count":150,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81573281"],"award-info":[{"award-number":["81573281"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602949"],"award-info":[{"award-number":["81602949"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008253","name":"Shaoxing University","doi-asserted-by":"publisher","award":["20175022"],"award-info":[{"award-number":["20175022"]}],"id":[{"id":"10.13039\/501100008253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008253","name":"Shaoxing University","doi-asserted-by":"publisher","award":["2018LG1001"],"award-info":[{"award-number":["2018LG1001"]}],"id":[{"id":"10.13039\/501100008253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejmech.2020.112117","type":"journal-article","created":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T11:34:59Z","timestamp":1580988899000},"page":"112117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Therapeutic potential of targeting SHP2 in human developmental disorders and cancers"],"prefix":"10.1016","volume":"190","author":[{"given":"Dadong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinlin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runpu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiyang","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.112117_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0968-0004(00)01712-6","article-title":"The regulation of protein function by multisite phosphorylation--a 25 year update","volume":"25","author":"Cohen","year":"2000","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib2","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.01592-13","article-title":"Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer","volume":"34","author":"Drake","year":"2014","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib3","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1134\/S0026893316010118","article-title":"The biological function of SHP2 in human disease","volume":"50","author":"Li","year":"2016","journal-title":"Mol. Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/febs.12077","article-title":"Protein tyrosine phosphatases - from housekeeping enzymes to master regulators of signal transduction","volume":"280","author":"Tonks","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2020.112117_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gde.2006.12.011","article-title":"The role of Shp2 (PTPN11) in cancer","volume":"17","author":"Mohi","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ejmech.2020.112117_bib6","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2004.05.018","article-title":"Protein tyrosine phosphatases in the human genome","volume":"117","author":"Alonso","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112117_bib7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1096\/fj.02-1212rev","article-title":"A\u00a0genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage","volume":"18","author":"Andersen","year":"2004","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112117_bib8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ni856","article-title":"Tyrosine phosphorylation of VHR phosphatase by ZAP-70","volume":"4","author":"Alonso","year":"2003","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejmech.2020.112117_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrc3037","article-title":"PTEN loss in the continuum of common cancers, rare syndromes and mouse models","volume":"11","author":"Hollander","year":"2011","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112117_bib10","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0962-8924(03)00175-2","article-title":"PTEN: from pathology to biology","volume":"13","author":"Sulis","year":"2003","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib11","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.2174\/1381612823666170616082125","article-title":"Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis","volume":"23","author":"Kim","year":"2017","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112117_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0065-230X(10)06002-1","article-title":"The tyrosine phosphatase Shp2 in development and cancer","volume":"106","author":"Grossmann","year":"2010","journal-title":"Adv. Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112117_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10555-008-9126-y","article-title":"The tyrosine phosphatase Shp2 (PTPN11) in cancer","volume":"27","author":"Chan","year":"2008","journal-title":"Cancer. Metastasis. Rev."},{"key":"10.1016\/j.ejmech.2020.112117_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2559.2008.03103.x","article-title":"SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis","volume":"53","author":"Zhou","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejmech.2020.112117_bib15","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jcmm.12618","article-title":"Functions of Shp2 in cancer","volume":"19","author":"Zhang","year":"2015","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2020.112117_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.semcdb.2014.09.013","article-title":"The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease","volume":"37","author":"Lauriol","year":"2015","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib17","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","article-title":"The \u2018Shp\u2019ing news: SH2 domain-containing tyrosine phosphatases in cell signaling","volume":"28","author":"Neel","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib18","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2174\/138161210791209027","article-title":"Targeting protein tyrosine phosphatases for anticancer drug discovery","volume":"16","author":"Scott","year":"2010","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112117_bib19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(00)80938-1","article-title":"Crystal structure of the tyrosine phosphatase SHP-2","volume":"92","author":"Hof","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112117_bib20","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1074\/jbc.M113.450023","article-title":"Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations","volume":"288","author":"Yu","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib21","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1038\/s41467-018-06823-9","article-title":"Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition","volume":"9","author":"LaRochelle","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112117_bib22","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1021\/jm901645u","article-title":"Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)","volume":"53","author":"Zhang","year":"2010","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1021\/acsmedchemlett.5b00118","article-title":"Exploring the existing drug space for novel pTyr mimetic and SHP2 inhibitors","volume":"6","author":"He","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.112117_bib24","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.1021\/acs.jmedchem.6b00680","article-title":"Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor","volume":"59","author":"Fortanet","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib25","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4155\/fmc.14.88","article-title":"Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention","volume":"6","author":"Butterworth","year":"2014","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib26","first-page":"771","article-title":"SH2 domain-containing protein-tyrosine phosphatases, handbook","volume":"98","author":"Neel","year":"2010","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2020.112117_bib27","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1038\/s41467-018-06814-w","article-title":"Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2","volume":"9","author":"Padua","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112117_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0969-2126(98)00027-6","article-title":"Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2","volume":"6","author":"Barford","year":"1998","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2020.112117_bib29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/s41467-019-09318-3","article-title":"Mitotic regulators and the SHP2-MAPK pathway promote IR endocytosis and feedback regulation of insulin signaling","volume":"10","author":"Choi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2020.112117_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166751","article-title":"Chlorogenic acid prevents osteoporosis by Shp2\/PI3K\/Akt pathway in ovariectomized rats","volume":"11","author":"Zhou","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112117_bib31","doi-asserted-by":"crossref","first-page":"113734","DOI":"10.18632\/oncotarget.22556","article-title":"Dietary quercetin potentiates the antiproliferative effect of interferon-\u03b1 in hepatocellular carcinoma cells through activation of JAK\/STAT pathway signaling by inhibition of SHP2 phosphatase","volume":"8","author":"Igbe","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112117_bib32","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/Mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2020.112117_bib33","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1074\/jbc.M410012200","article-title":"A\u00a0novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation","volume":"280","author":"Montagner","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib34","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1073\/pnas.1119803109","article-title":"Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature","volume":"109","author":"Serra-Nedelec","year":"2012","journal-title":"P.\u00a0Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2020.112117_bib35","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S1097-2765(04)00050-4","article-title":"Shp2 regulates Src family kinase activity and ras\/erk activation by controlling Csk recruitment","volume":"13","author":"Zhang","year":"2004","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2020.112117_bib36","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1074\/jbc.M312575200","article-title":"Roles of Gab1 and SHP2 in paxillin tyrosine dephosphorylation and Src activation in response to epidermal growth factor","volume":"279","author":"Ren","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib37","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1349-7006.2009.01257.x","article-title":"Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation","volume":"100","author":"Matozaki","year":"2009","journal-title":"Canc. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib38","doi-asserted-by":"crossref","first-page":"22992","DOI":"10.1074\/jbc.M312498200","article-title":"Shp2, an SH2-containing protein-tyrosine phosphatase, positively regulates receptor tyrosine kinase signaling by dephosphorylating and inactivating the inhibitor Sprouty","volume":"279","author":"Hanafusa","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/BJ20050229","article-title":"Participation of both Gab1 and Gab2 in the activation of the ERK\/MAPK pathway by epidermal growth factor","volume":"391","author":"Meng","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2020.112117_bib40","doi-asserted-by":"crossref","first-page":"24380","DOI":"10.1074\/jbc.M010275200","article-title":"Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2","volume":"276","author":"Cunnick","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib41","first-page":"571","article-title":"Frs2alpha and Shp2 signal independently of Gab to mediate FGF signaling in lens development","volume":"127","author":"Li","year":"2014","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib42","doi-asserted-by":"crossref","first-page":"11479","DOI":"10.1016\/S0021-9258(19)50220-4","article-title":"The insulin receptor substrate 1 associates with the SH2-containing phosphotyrosine phosphatase syp","volume":"268","author":"Kuhne","year":"1993","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112117_bib44","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1038\/sj.onc.1209728","article-title":"Modulation of alpha-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3","volume":"25","author":"Burks","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112117_bib45","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1210\/en.2005-1115","article-title":"Recruitment of the tyrosine phosphatase Src homology 2 domain tyrosine phosphatase-2 to the p85 subunit of phosphatidylinositol-3 (PI-3) kinase is required for insulin-like growth factor-I-dependent PI-3 kinase activation in smooth muscle cells","volume":"147","author":"Kwon","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2020.112117_bib46","doi-asserted-by":"crossref","first-page":"6909","DOI":"10.1038\/sj.onc.1206798","article-title":"The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3","volume":"22","author":"Agazie","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112117_bib47","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jcp.10446","article-title":"SHP-2 regulates the phosphatidylinositide 3\u2019-kinase\/Akt pathway and suppresses caspase 3-mediated apoptosis","volume":"199","author":"Zito","year":"2004","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2020.112117_bib48","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1128\/MCB.22.12.4062-4072.2002","article-title":"Receptor-specific regulation of phosphatidylinositol 3\u2019-kinase activation by the protein tyrosine phosphatase Shp2","volume":"22","author":"Zhang","year":"2002","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib49","doi-asserted-by":"crossref","first-page":"30245","DOI":"10.1038\/srep30245","article-title":"Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown","volume":"6","author":"Srikar","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112117_bib50","doi-asserted-by":"crossref","first-page":"20471","DOI":"10.1038\/srep20471","article-title":"A\u00a0cross-species study of PI3K protein-protein interactions reveals the direct interaction of P85 and SHP2","volume":"6","author":"Breitkopf","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2020.112117_bib51","article-title":"Computational model of gab1\/2-dependent VEGFR2 pathway to Akt activation","volume":"8","author":"Tan","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112117_bib52","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.2741\/3051","article-title":"Protein tyrosine phosphatases in the JAK\/STAT pathway","volume":"13","author":"Xu","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2020.112117_bib53","doi-asserted-by":"crossref","first-page":"5995","DOI":"10.1038\/sj.onc.1206846","article-title":"Catalytic-dependent and -independent roles of SHP-2 tyrosine phosphatase in interleukin-3 signaling","volume":"22","author":"Yu","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112117_bib54","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1038\/sj.onc.1207471","article-title":"A\u00a0negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival","volume":"23","author":"Chen","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112117_bib55","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1074\/jbc.275.7.5208","article-title":"Requirement for protein-tyrosine phosphatase SHP-2 in insulin-induced activation of c-jun NH2-terminal kinase","volume":"275","author":"Fukunaga","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib56","first-page":"1251","article-title":"The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury","volume":"22","author":"Chong","year":"2007","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ejmech.2020.112117_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.193.1.101","article-title":"Modulation of the nuclear factor kappa B pathway by Shp-2 tyrosine phosphatase in mediating the induction of interleukin (IL)-6 by IL-1 or tumor necrosis factor","volume":"193","author":"You","year":"2001","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2020.112117_bib58","doi-asserted-by":"crossref","first-page":"31107","DOI":"10.1074\/jbc.M200156200","article-title":"Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells","volume":"277","author":"Chughtai","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib59","doi-asserted-by":"crossref","first-page":"33155","DOI":"10.1074\/jbc.M805138200","article-title":"Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase","volume":"283","author":"Jakob","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib60","doi-asserted-by":"crossref","first-page":"15208","DOI":"10.1074\/jbc.M211327200","article-title":"Role of SHP-2 tyrosine phosphatase in the DNA damage-induced cell death response","volume":"278","author":"Yuan","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib61","doi-asserted-by":"crossref","first-page":"42701","DOI":"10.1074\/jbc.M506768200","article-title":"SHP-2 phosphatase regulates DNA damage-induced apoptosis and G2\/M arrest in catalytically dependent and independent manners, respectively","volume":"280","author":"Yuan","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib62","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2010-06-288910","article-title":"A\u00a0critical role for SHP2 in STAT5 activation and growth factor-mediated proliferation, survival, and differentiation of human CD34+ cells","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112117_bib63","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.2147\/OTT.S138833","article-title":"SHP2 overexpression enhances the invasion and metastasis of ovarian cancer in\u00a0vitro and in\u00a0vivo","volume":"10","author":"Hu","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2020.112117_bib64","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2010-11-319517","article-title":"Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells","volume":"117","author":"Chan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112117_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094884","article-title":"Distinct and overlapping functions of ptpn11 genes in Zebrafish development","volume":"9","author":"Bonetti","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.ejmech.2020.112117_bib66","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6807-14-10","article-title":"Structural insights into Noonan\/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)","volume":"14","author":"Qiu","year":"2014","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib67","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/499925","article-title":"Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease","volume":"78","author":"Tartaglia","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2174\/1568009614666140717105001","article-title":"Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis","volume":"14","author":"Huang","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2020.112117_bib69","first-page":"E14","article-title":"Noonan syndrome","volume":"50","author":"A.M","year":"2014","journal-title":"J.\u00a0Paediatr. Child Health"},{"key":"10.1016\/j.ejmech.2020.112117_bib70","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s10038-005-0239-7","article-title":"Functional analysis of PTPN11\/SHP-2 mutants identified in Noonan syndrome and childhood leukemia","volume":"50","author":"Niihori","year":"2005","journal-title":"J.\u00a0Hum. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib71","doi-asserted-by":"crossref","first-page":"30984","DOI":"10.1074\/jbc.M504699200","article-title":"Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes","volume":"280","author":"Keilhack","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib72","doi-asserted-by":"crossref","first-page":"27066","DOI":"10.1074\/jbc.M112.350231","article-title":"Counteracting effects operating on Src homology 2 domain-containing protein-tyrosine phosphatase 2 (SHP2) function drive selection of the recurrent Y62D and Y63C substitutions in Noonan syndrome","volume":"287","author":"Martinelli","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib73","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/nn.3863","article-title":"Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome","volume":"17","author":"Lee","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejmech.2020.112117_bib74","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddy133","article-title":"Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib75","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1471-2415-13-70","article-title":"MAPK activation in mature cataract associated with Noonan syndrome","volume":"13","author":"Hashida","year":"2013","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ejmech.2020.112117_bib76","first-page":"13","article-title":"Leopard syndrome, orphanet","volume":"3","author":"Sarkozy","year":"2008","journal-title":"J.\u00a0Rare. Dis."},{"key":"10.1016\/j.ejmech.2020.112117_bib77","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.00646-09","article-title":"Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase\/AKT\/glycogen synthase kinase 3 signaling","volume":"30","author":"Edouard","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib78","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib79","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1021\/bi5002695","article-title":"Molecular basis of gain-of-function LEOPARD syndrome-associated SHP2 mutations","volume":"53","author":"Yu","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2020.112117_bib80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/hmg\/ddn336","article-title":"Phosphatase-defective LEOPARD syndrome mutations in PTPN11 gene have gain-of-function effects during Drosophila development","volume":"18","author":"Oishi","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib81","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2340\/00015555-2123","article-title":"Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation","volume":"95","author":"Motegi","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.ejmech.2020.112117_bib82","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/MOH.0000000000000345","article-title":"Role of SHP2 in hematopoiesis and leukemogenesis","volume":"24","author":"Pandey","year":"2017","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ejmech.2020.112117_bib83","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","article-title":"SHP2 sails from physiology to pathology","volume":"58","author":"Tajan","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib84","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2004-10-4057","article-title":"Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia","volume":"106","author":"Xu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2020.112117_bib85","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.20110450","article-title":"Non-lineage\/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells","volume":"208","author":"Xu","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ejmech.2020.112117_bib86","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.2174\/1381612824666181106100837","article-title":"The landscape of protein tyrosine phosphatase (Shp2) and cancer","volume":"24","author":"Rehman","year":"2018","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2020.112117_bib87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejmg.2005.03.001","article-title":"Germ-line and somatic PTPN11 mutations in human disease","volume":"48","author":"Tartaglia","year":"2005","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.ejmech.2020.112117_bib88","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ccr.2005.01.010","article-title":"Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations","volume":"7","author":"Mohi","year":"2005","journal-title":"Canc. Cell"},{"key":"10.1016\/j.ejmech.2020.112117_bib89","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1074\/jbc.M507622200","article-title":"Effects of a leukemia-associated gain-of-function mutation of SHP-2 phosphatase on interleukin-3 signaling","volume":"281","author":"Yu","year":"2006","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib90","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/leu.2016.326","article-title":"Inhibition of the Gab2\/PI3K\/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations","volume":"31","author":"Liu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2020.112117_bib91","doi-asserted-by":"crossref","first-page":"8816","DOI":"10.1158\/0008-5472.CAN-04-1923","article-title":"Activating mutations of the noonan syndrome-associated SHP2\/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia","volume":"64","author":"Bentires-Alj","year":"2004","journal-title":"Canc. Res."},{"key":"10.1016\/j.ejmech.2020.112117_bib92","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1038\/sj.onc.1211019","article-title":"Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumors","volume":"27","author":"Miyamoto","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2020.112117_bib93","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/cdd.2008.54","article-title":"Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells","volume":"15","author":"Zhou","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2020.112117_bib94","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3390\/ijms18020395","article-title":"Shp2 plays a critical role in IL-6-induced EMT in breast cancer cells","volume":"18","author":"Sun","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib95","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nm.2645","article-title":"Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop","volume":"18","author":"Aceto","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112117_bib96","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nm1341","article-title":"A\u00a0role for the scaffolding adapter GAB2 in breast cancer","volume":"12","author":"Bentires-Alj","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.112117_bib97","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.3892\/mmr.2015.3951","article-title":"Structure and function of Gab2 and its role in cancer (Review)","volume":"12","author":"Ding","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2020.112117_bib98","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1128\/MCB.01353-12","article-title":"Gab2 phosphorylation by RSK inhibits Shp2 recruitment and cell motility","volume":"33","author":"Zhang","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib99","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nrc1433","article-title":"Oncogenic mechanisms of the Helicobacter pylori CagA protein","volume":"4","author":"Hatakeyama","year":"2004","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112117_bib100","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1074\/jbc.M309964200","article-title":"Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation","volume":"279","author":"Higashi","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib101","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1349-7006.2004.tb03229.x","article-title":"Conditional gene silencing utilizing the lac repressor reveals a role of SHP-2 in cagA-positive Helicobacter pylori pathogenicity","volume":"95","author":"Higuchi","year":"2004","journal-title":"Canc. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib102","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1096\/fj.01-0766fje","article-title":"B-Raf\/Rap1 signaling, but not c-Raf-1\/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection","volume":"16","author":"Wessler","year":"2002","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2020.112117_bib103","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.imbio.2012.01.001","article-title":"Regulation of SHP2 by PTEN\/AKT\/GSK-3beta signaling facilitates IFN-gamma resistance in hyperproliferating gastric cancer","volume":"217","author":"Tseng","year":"2012","journal-title":"Immunobiology"},{"key":"10.1016\/j.ejmech.2020.112117_bib104","first-page":"2083","article-title":"Expression and clinical significance of SHP2 in gastric cancer","volume":"40","author":"Dong","year":"2012","journal-title":"J.\u00a0Int. Med. Res."},{"key":"10.1016\/j.ejmech.2020.112117_bib105","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1007\/s10620-009-0924-z","article-title":"Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas","volume":"55","author":"Kim","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2020.112117_bib106","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/carcin\/bgu025","article-title":"SHP2E76K mutant promotes lung tumorigenesis in transgenic mice","volume":"35","author":"Schneeberger","year":"2014","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2020.112117_bib107","doi-asserted-by":"crossref","first-page":"91123","DOI":"10.18632\/oncotarget.20249","article-title":"Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1\/2 pathway activation in non-small cell lung cancer cells","volume":"8","author":"Sun","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112117_bib108","first-page":"629","article-title":"Ptpn11\/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis, Cancer","volume":"19","author":"Bard-Chapeau","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112117_bib109","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00432-011-1143-5","article-title":"The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma","volume":"138","author":"Jiang","year":"2012","journal-title":"J.\u00a0Cancer. Res. Clin."},{"key":"10.1016\/j.ejmech.2020.112117_bib110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.biopha.2013.10.012","article-title":"Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer","volume":"68","author":"Cai","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2020.112117_bib111","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1158\/1535-7163.MCT-13-0378","article-title":"Embelin reduces colitis-associated tumorigenesis through limiting IL-6\/STAT3 signaling","volume":"13","author":"Dai","year":"2014","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112117_bib112","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1128\/MCB.00043-13","article-title":"Epithelial tyrosine phosphatase SHP-2 protects against intestinal inflammation in mice","volume":"33","author":"Coulombe","year":"2013","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib113","doi-asserted-by":"crossref","first-page":"7586","DOI":"10.18632\/oncotarget.13812","article-title":"T\u00a0lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2020.112117_bib114","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature12396","article-title":"Ptpn11 deletion in a novel progenitor causes metachondromatosis by inducing hedgehog signalling","volume":"499","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2020.112117_bib115","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/jbmr.2062","article-title":"Targeted disruption of Shp2 in chondrocytes leads to metachondromatosis with multiple cartilaginous protrusions","volume":"29","author":"Kim","year":"2014","journal-title":"J.\u00a0Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2020.112117_bib116","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2478\/s11658-012-0020-9","article-title":"SHP-2 and PTP-pest induction during Rb-E2F associated apoptosis","volume":"17","author":"Morales","year":"2012","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2020.112117_bib117","doi-asserted-by":"crossref","first-page":"152621","DOI":"10.1016\/j.prp.2019.152621","article-title":"Shp2 expression is upregulated in cervical cancer, and Shp2 contributes to cell growth and migration and reduces sensitivity to cisplatin in cervical cancer cells","volume":"215","author":"Cao","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.ejmech.2020.112117_bib118","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1186\/1471-2407-14-442","article-title":"Src-homology 2 domain-containing tyrosine phosphatase 2 promotes oral cancer invasion and metastasis","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Canc."},{"key":"10.1016\/j.ejmech.2020.112117_bib119","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4155\/fmc.10.241","article-title":"Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development","volume":"2","author":"Barr","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib120","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.4049\/jimmunol.167.6.3391","article-title":"Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines","volume":"167","author":"Pathak","year":"2001","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2020.112117_bib121","doi-asserted-by":"crossref","first-page":"47311","DOI":"10.1074\/jbc.M106568200","article-title":"Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure","volume":"276","author":"Shen","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib122","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0968-0896(03)00039-7","article-title":"Structure-Based design and discovery of novel inhibitors of protein tyrosine phosphatases","volume":"11","author":"Huang","year":"2003","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib123","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1073\/pnas.0601490103","article-title":"Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis","volume":"103","author":"Noren-Muller","year":"2006","journal-title":"P.\u00a0Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2020.112117_bib124","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1124\/mol.106.025536","article-title":"Discovery of a novel shp2 protein tyrosine phosphatase inhibitor","volume":"70","author":"Chen","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112117_bib125","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1021\/jm8002526","article-title":"Inhibitors of Src homology-2 domain containing protein tyrosine phosphatase-2 (Shp2) based on oxindole scaffolds","volume":"51","author":"Lawrence","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib126","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.bcp.2010.05.019","article-title":"Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112","volume":"80","author":"Chen","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2020.112117_bib127","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1073\/pnas.0710468105","article-title":"Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking","volume":"105","author":"Hellmuth","year":"2008","journal-title":"P.\u00a0Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2020.112117_bib128","doi-asserted-by":"crossref","first-page":"5221","DOI":"10.1021\/jm8004306","article-title":"2-Thiazolylimino\/Heteroarylimino-5-arylidene-4-thiazolidinones as new agents with SHP-2 inhibitory action","volume":"51","author":"Geronikaki","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib129","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1021\/jm701496h","article-title":"Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase\/lipoxygenase inhibition","volume":"51","author":"Geronikaki","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib130","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1021\/jm800229d","article-title":"Identification of small molecular weight inhibitors of Src homology 2 domain-containing tyrosine phosphatase 2 (SHP-2) via in silico database screening combined with experimental assay","volume":"51","author":"Yu","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib131","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1158\/1535-7163.MCT-13-0049-T","article-title":"Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies","volume":"12","author":"Yu","year":"2013","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.ejmech.2020.112117_bib132","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.1021\/jm800456k","volume":"51","author":"Dawson","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib133","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1074\/jbc.M807241200","article-title":"GLEPP1\/protein-tyrosine phosphatase phi inhibitors block chemotaxis in\u00a0vitro and in\u00a0vivo and improve murine ulcerative colitis","volume":"284","author":"Gobert","year":"2009","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib134","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1021\/jm5006176","article-title":"Therapeutic potential of targeting the oncogenic SHP2 phosphatase","volume":"57","author":"Zeng","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib135","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.1021\/jm400248c","article-title":"A\u00a0potent and selective small-molecule inhibitor for the lymphoid-specific tyrosine phosphatase (LYP), a target associated with autoimmune diseases","volume":"56","author":"He","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib136","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.4049\/jimmunol.0903562","article-title":"Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents","volume":"184","author":"Kundu","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ejmech.2020.112117_bib137","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.bmcl.2010.11.117","article-title":"Shp2 protein tyrosine phosphatase inhibitor activity of estramustine phosphate and its triterpenoid analogs","volume":"21","author":"Scott","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2020.112117_bib138","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.chembiol.2010.10.015","article-title":"SHP2 is a target of the immunosuppressant tautomycetin","volume":"18","author":"Liu","year":"2011","journal-title":"Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib139","doi-asserted-by":"crossref","first-page":"7212","DOI":"10.1021\/jm400474r","article-title":"Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11)","volume":"56","author":"Liu","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib140","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/acs.jmedchem.8b01725","article-title":"Optimization of fused bicyclic allosteric SHP2 inhibitors","volume":"62","author":"Bagdanoff","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib141","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1021\/acs.jmedchem.8b01726","article-title":"6-Amino-3-methylpyrimidinones as potent, selective, and orally efficacious SHP2 inhibitors","volume":"62","author":"Sarver","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib142","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1021\/acs.jmedchem.7b01520","article-title":"Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment","volume":"60","author":"Xie","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib143","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10822-019-00213-z","article-title":"Structure based design of selective SHP2 inhibitors by De novo design, synthesis and biological evaluation","volume":"33","author":"Liu","year":"2019","journal-title":"J.\u00a0Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejmech.2020.112117_bib144","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1021\/acs.jmedchem.8b00513","article-title":"Small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2","volume":"62","author":"Wu","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.112117_bib145","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1021\/acschembio.7b00980","article-title":"Dual allosteric inhibition of SHP2 phosphatase","volume":"13","author":"Fodor","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2020.112117_bib146","doi-asserted-by":"crossref","first-page":"15763","DOI":"10.1021\/acsomega.8b02200","article-title":"The allosteric site on SHP2\u2019s protein tyrosine phosphatase domain is targetable with druglike small molecules","volume":"3","author":"Marsh-Armstrong","year":"2018","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2020.112117_bib147","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cell.2008.11.038","article-title":"Large-scale structural analysis of the classical human protein tyrosine phosphatome","volume":"136","author":"Barr","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2020.112117_bib148","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Canc."},{"key":"10.1016\/j.ejmech.2020.112117_bib149","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.drup.2005.11.002","article-title":"Tailoring Ras-pathway--inhibitor combinations for cancer therapy","volume":"8","author":"Blum","year":"2005","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2020.112117_bib150","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1158\/0008-5472.CAN-14-1215","article-title":"PD-1\/SHP-2 inhibits Tc1\/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment","volume":"75","author":"Li","year":"2015","journal-title":"Canc. Res."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420300842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420300842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:06:18Z","timestamp":1759327578000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420300842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":150,"alternative-id":["S0223523420300842"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112117","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of targeting SHP2 in human developmental disorders and cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.112117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"112117"}}